We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
VOXZOGO vosoritide 0.56 mg powder for injection vial and diluent pre-filled syringe, BioMarin Pharmaceutical Australia Pty Ltd, CON-1107
Product name
VOXZOGO vosoritide 0.56 mg powder for injection vial and diluent pre-filled syringe
Sponsor name
BioMarin Pharmaceutical Australia Pty Ltd
Consent start
Consent no.
CON-1107
Duration
The consent is effective from 16 January 2023 until 31 July 2023.
The consent is effective for all batches of the product that are labelled as per the international English/ bilingual language pack for marketing in the EU (as described in the consent letter) imported into and supplied in Australia.
The consent is effective for all batches of the product that are labelled as per the international English/ bilingual language pack for marketing in the EU (as described in the consent letter) imported into and supplied in Australia.
Standard
Carton
section 8(1)(h), section 8(1)(d), section 8(1)(l), section 8(1)(l)(iii), section 9(3)(a), section 10(3)(a), section 10(3)(b)
Vial label
section 10(5)(d), section 10(5)(h)
Intermediate packaging label (diluent syringe tray)
section 8(3)(a), section 8(3)(c), section 8(3)(f)
Diluent syringe label
section 10(5)(d) of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
section 8(1)(h), section 8(1)(d), section 8(1)(l), section 8(1)(l)(iii), section 9(3)(a), section 10(3)(a), section 10(3)(b)
Vial label
section 10(5)(d), section 10(5)(h)
Intermediate packaging label (diluent syringe tray)
section 8(3)(a), section 8(3)(c), section 8(3)(f)
Diluent syringe label
section 10(5)(d) of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Non-compliance with standard
The products are labelled as per the international English / bilingual language pack for marketing in the EU.
Conditions imposed
1. The consent only applies to affected batches (international English/ bilingual language pack for marketing in the EU) imported into and supplied in Australia on or before 31st July 2023.
2. The Sponsor will advise pharmacies and affected healthcare providers of the temporary use of international labels, including links to the Australian Product Information (PI) and Consumer Medicine Information (CMI).
3. The Sponsor will over-sticker the carton label to include:
a. the Australian Sponsor’s details on the main label prefaced by “Supplied by:” to make it clear to consumers it is the Australian distributor.
b. the AUST R number.
c. signal heading 'PRESCRIPTION ONLY MEDICINE' and cautionary statement 'KEEP OUT OF REACH OF CHILDREN'.
d. the statement “Refer to the Australian CMI available at www.biomarin.com/en-au/voxzogoconsumer-medicine-information/” on the main label to allow patients and their carers easy access to the Australian approved CMI which also includes Instructions for use.
Import, Supply, &/or Export
import and supply
Therapeutic product type
Prescription medicines